KR950703527A - 프로스타글란딘 유도체 - Google Patents
프로스타글란딘 유도체 Download PDFInfo
- Publication number
- KR950703527A KR950703527A KR1019950701485A KR19950701485A KR950703527A KR 950703527 A KR950703527 A KR 950703527A KR 1019950701485 A KR1019950701485 A KR 1019950701485A KR 19950701485 A KR19950701485 A KR 19950701485A KR 950703527 A KR950703527 A KR 950703527A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutically acceptable
- compound
- formula
- acceptable salt
- disease
- Prior art date
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 208000017169 kidney disease Diseases 0.000 claims abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 2
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims abstract 2
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims abstract 2
- 229940127218 antiplatelet drug Drugs 0.000 claims abstract 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract 2
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims abstract 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
식
(식중, R1은 수소원자 또는 C1∼C6알킬기를 나타내고, R2는 시클로헥실기 또는 시클로펜틸메틸기를 나타낸다)로 표시되는 프로스타글랄딘 유도체 및 그의 염, 본 발명 화합물은 혈소판 응집억제작용, 신장혈관 및 관혈관 확장작용 등의 생리활성을 가지며, 신장질환이나 순환기 질환의 처치를 위해 유용하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- 식(식중, R1은 수소원자 또는 C1∼C6알킬기를 나타내고, R2는 시클로헥실기 또는 시클로펜틸메틸기를 나타낸다)로 표시되는 프로스타글랄딘 유도체 및 그의 염.
- 청구범위 제1항 기재의 식(I)화합물 또는 제약학적으로 허용되는 그의 염을 함유하는 약제.
- 청구범위 제1항의 기재의 식(I)화합물 또는 제약학적으로 허용되는 그의 염을 함유하는 혈소판 응집 억제제.
- 청구범위 제1항의 기재의 식(I)화합물 또는 제약학적으로 허용되는 그의 염을 함유하는 신장질환 및 순환기 질환 처치제.
- 청구범위 제1항의 기재의 식(I)화합물 또는 제약학적으로 허용되는 그의 염 및 제약학적으로 허용되는 첨가제로 된 약학적 조성물.
- 청구범위 제1항의 기재의 식(I)화합물 또는 제약학적으로 허용되는 그의 염의 유효량을 포유동물에 투여하는 것으로 되는 포유동물의 신장질환 또는 순환기질환의 처치방법.
- 청구범위 제1항의 기재의 식(I)화합물 또는 제약학적으로 허용되는 그의 염의 질병의 처치를 위한 사용.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28200192 | 1992-10-20 | ||
JP282001/1992 | 1992-10-20 | ||
PCT/JP1993/001493 WO1994008959A1 (en) | 1992-10-20 | 1993-10-18 | Prostaglandine derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950703527A true KR950703527A (ko) | 1995-09-20 |
Family
ID=17646845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950701485A KR950703527A (ko) | 1992-10-20 | 1993-10-18 | 프로스타글란딘 유도체 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5545666A (ko) |
EP (1) | EP0666256A1 (ko) |
KR (1) | KR950703527A (ko) |
AU (1) | AU669226B2 (ko) |
CA (1) | CA2147476A1 (ko) |
WO (1) | WO1994008959A1 (ko) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE144769T1 (de) * | 1991-04-22 | 1996-11-15 | Taisho Pharmaceutical Co Ltd | Prostaglandin e1-analoge |
EP0652211A1 (en) * | 1992-07-24 | 1995-05-10 | Taisho Pharmaceutical Co. Ltd | Prostaglandin derivative |
FR2746308B1 (fr) * | 1996-03-22 | 1998-04-30 | Oreal | Compositions de teinture des fibres keratiniques contenant des imidazolo-azoles ; leur utilisation en teinture comme coupleurs ; procede de teinture |
FR2746391B1 (fr) | 1996-03-22 | 1998-04-17 | Oreal | Compositions cosmetiques a base de pyrazolin-4,5-diones, nouvelles pyrazolin-4,5 diones, procedes de preparation et utilisations |
FR2746307B1 (fr) | 1996-03-22 | 1998-04-30 | Oreal | Compositions de teinture des fibres keratiniques contenant des pyrrolo-azoles ; utilisation comme coupleurs ; procede de teinture |
FR2746309B1 (fr) | 1996-03-22 | 1998-04-17 | Oreal | Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture |
FR2746310B1 (fr) | 1996-03-22 | 1998-06-12 | Oreal | Compositions de teinture des fibres keratiniques contenant des pyrazolin-3,5-dione ; leur utilisation pour la teinture comme coupleurs, procede de teinture |
FR2746306B1 (fr) * | 1996-03-22 | 1998-04-30 | Oreal | Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles ; leur utilisation pour la teinture comme coupleurs, procede de teinture |
US6235780B1 (en) * | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
DK1211242T3 (da) * | 1999-09-10 | 2010-04-26 | Taisho Pharmaceutical Co Ltd | Prostaglandinderivater |
WO2001037839A1 (fr) * | 1999-11-24 | 2001-05-31 | Taisho Pharmaceutical Co., Ltd. | Preparation s'administrant par voie nasale |
US20040266880A1 (en) * | 2002-02-22 | 2004-12-30 | Fumie Sato | Antipruritics |
MXPA04004371A (es) * | 2002-08-09 | 2004-08-13 | Taisho Pharmaceutical Co Ltd | Agente antipruritico. |
US7737182B2 (en) * | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
AU2003301900A1 (en) * | 2002-11-13 | 2004-06-03 | Fumie Sato | Antipruritic drug |
US11958818B2 (en) | 2019-05-01 | 2024-04-16 | Boehringer Ingelheim International Gmbh | (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029681A (en) * | 1976-02-13 | 1977-06-14 | The Upjohn Company | 13,14-Didehydro-PG analogs |
ES2054860T5 (es) * | 1987-07-17 | 2003-11-01 | Schering Ag | Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos. |
DE3831222A1 (de) * | 1988-09-09 | 1990-03-22 | Schering Ag | 6-oxo-9-fluor-prostaglandin-derivate verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
JP2502009B2 (ja) | 1992-06-08 | 1996-05-29 | サンデン株式会社 | 自動販売機 |
EP0652211A1 (en) * | 1992-07-24 | 1995-05-10 | Taisho Pharmaceutical Co. Ltd | Prostaglandin derivative |
DE4330177A1 (de) * | 1993-08-31 | 1995-03-02 | Schering Ag | Neue 9-Chlor-prostaglandin-derivate |
-
1993
- 1993-10-18 EP EP93922647A patent/EP0666256A1/en not_active Withdrawn
- 1993-10-18 WO PCT/JP1993/001493 patent/WO1994008959A1/ja not_active Application Discontinuation
- 1993-10-18 US US08/290,745 patent/US5545666A/en not_active Expired - Fee Related
- 1993-10-18 KR KR1019950701485A patent/KR950703527A/ko not_active Application Discontinuation
- 1993-10-18 CA CA002147476A patent/CA2147476A1/en not_active Abandoned
- 1993-10-18 AU AU51568/93A patent/AU669226B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CA2147476A1 (en) | 1994-04-28 |
AU669226B2 (en) | 1996-05-30 |
AU5156893A (en) | 1994-05-09 |
EP0666256A1 (en) | 1995-08-09 |
WO1994008959A1 (en) | 1994-04-28 |
US5545666A (en) | 1996-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950703527A (ko) | 프로스타글란딘 유도체 | |
KR920002144A (ko) | 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제 | |
KR890011592A (ko) | 기관내 허혈병의 치료용 조성물 | |
KR890016966A (ko) | 신규 항바이러스제 | |
ES2155093T3 (es) | Nuevos inhibidores de la uridina fosforilasa (urdpasa) y de la dihidrouracil deshidrogenasa (dhudasa). | |
KR950014067A (ko) | 아릴아미드유도체 | |
KR940005274A (ko) | 쇼그렌(Sjoegren)증후군 치료제 | |
KR950016727A (ko) | 트롬보모듈린 발현을 증가시키는 방법 | |
KR900016135A (ko) | 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체 | |
KR900001643A (ko) | 항균제 | |
KR910004191A (ko) | 신질환치료제 | |
KR950016760A (ko) | 치질 치료제 | |
KR950702554A (ko) | 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents) | |
KR940702491A (ko) | 옥사졸리돈 유도체 | |
KR950703941A (ko) | 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor) | |
KR910018348A (ko) | 술포닐아미노치환 비시클로환계 히드록삼산 유도체 | |
KR940702726A (ko) | 치환된 퀴놀린-3-카르복시아미드 화합물의 용도 및 이를 이용한 다발성 경화증의 치료방법 | |
KR890012942A (ko) | 5-치환된 오르니틴 유도체 | |
KR890008136A (ko) | 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체 | |
KR950703528A (ko) | 프로스타글란딘 e₁유연체 | |
KR950702544A (ko) | 비페닐메탄 유도체 및 이를 함유하는 약제 | |
KR980002033A (ko) | 트리아졸 유도체 또는 그 염 | |
KR960703843A (ko) | 아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient) | |
BR9610878A (pt) | Composição farmacêutica para administração intravenosa a um paciente e processo para inibir a agregaçao de plaquetas sanguíneas em mamiferos | |
KR960700711A (ko) | 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |